Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Number of employees : 42 people.
Managers
Name Title Age Since
Richard A. Miller, Dr. Chairman, President & Chief Executive Officer 69 2014
Leiv Lea Chief Financial Officer 66 -
Mehrdad Mobasher, Dr. Chief Medical Officer & Senior Vice President 47 -
Peter A. Thompson, Dr. Independent Director 60 2014
Elisha P. Gould Independent Director 63 2014
Scott W. Morrison Independent Director 62 2015
Ian T. Clark Independent Director 60 2017
Linda S. Grais, Dr. Independent Director 63 2019
Edith P. Mitchell, Dr. Independent Director 72 2020
Joseph J. Buggy, Dr. Executive Vice President-Discovery Research 53 2014
Members of the board
Name Title Age Since
Richard A. Miller, Dr. Chairman, President & Chief Executive Officer 69 2014
Peter A. Thompson, Dr. Independent Director 60 2014
Elisha P. Gould Independent Director 63 2014
Scott W. Morrison Independent Director 62 2015
Ian T. Clark Independent Director 60 2017
Linda S. Grais, Dr. Independent Director 63 2019
Edith P. Mitchell, Dr. Independent Director 72 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 42,421,159 37,498,176 88.4% 0 0.0% 88.4%
Shareholders
NameEquities%
OrbiMed Advisors Private Equity 8,053,298 19.0%
BVF Partners LP 3,678,626 8.67%
Ecor1 Capital LLC 3,579,377 8.44%
Adams Street Partners LLC 3,275,616 7.72%
Richard A. Miller 1,324,229 3.12%
The Vanguard Group, Inc. 1,102,822 2.60%
Novo Holdings A/S (Investment Company) 847,906 2.00%
CHI Advisors LLC 719,132 1.70%
Renaissance Technologies LLC 658,070 1.55%
T. Rowe Price Associates, Inc. (Investment Management) 647,174 1.53%
Company contact information
Corvus Pharmaceuticals, Inc.
863 Mitten Road
Suite 102
Burlingame, CA 94010

Phone : +1.650.900.4520
Web : http://www.corvuspharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Corvus Pharmaceuticals, Inc.
Sector Other Biotechnology & Medical Research